Table 1 Characteristics of the patients who underwent ablation

Age (years) mean ± SD

64.5 ± 10.2

63.6 ± 9.1

0.66

Sex (M/F)

35/11

32/15

0.49

Body mass index (kg/m²) mean ± SD

24.8 ± 4.2

23.9 ± 5.4

0.67

CHADS₂ score median (min-max)

1 (0–4)

1 (0–5)

0.99

CHA₂DS₂-VASc score median (min-max)

2 (0–5)

2 (0–7)

0.87

Creatinine clearance (mL/min) mean ± SD

86.3 ± 27.1

81.2 ± 26.7

0.36

Left atrial dimension (LAD)(cm) mean ± SD

3.71 ± 0.57

3.86 ± 0.65

0.27

Left ventricular ejection fraction (LVEF) (%) mean ± SD

69.24 ± 6.15

63.89 ± 9.19

< 0.01

Average Drug Use (mg) mean ± SD

0.18 ± 0.05

1.06 ± 0.35

–

Dexmedetomidine hydrochloride (μg) median (min-max)

107.2 (46.0–201.6)

117.2 (61.6–282.4)

0.14

Patients who received cardioversion No. of patients (percentage of patients)

25 (54.3%)

26 (55.3%)

1.00

 Paroxysmal. No. of patients (percentage of patients)

31 (67.4%)

29 (61.7%)

0.83

 Persistent No. of patients (percentage of patients)

13 (28.2%)

15 (31.9%)

 Long lasting persistent No. of patients (percentage of patients)

2 (4.3%)

3 (6.4%)

 PVI No. of patients (percentage of patients)

31 (67.4%)

31 (66.0%)

0.45

 PVI + CTI ablation No. of patients (percentage of patients)

9 (19.6%)

13 (27.7%)

Other No. of patients (percentage of patients)

6 (13.0%)

3 (6.4%)